Given the tumor-promoting (e.g., BiP/GRP78, PDI) and tumor-opposing (e.g., calreticulin) activities of ER chaperones and oxidoreductases, current knowledge suggests more pinpointed approaches are needed to increase efficacy of ER-targeted cancer chemotherapeutic strategies. Here, HSPA5 is linked to neoplasm.